Amgen’s Tavneos: When Approval No Longer Settles the Evidence
Examine how trial reliability, regulatory proceedings, and patient questions reshape the assessment of an acquired drug.
12 min readRead more
THE READING ROOM
A closer look at the story.
Read into the mechanisms, evidence, and trade-offs behind a result. Sources and evidence dates stay with each story.
3 English texts
Explore after approvalThe evidence.GENMAB · RINA-S
Genmab’s Rina-S: Revisiting a $1.8 Billion Acquisition
What does a successful trial tell us about a decision made two and a half years earlier?
8 min readRead more
A better future?IgA NEPHROPATHY
Lower Urine Protein. Better Kidney Protection?
An episode transcript on early signals, accelerated approval, and the long-term outcomes patients care about.
7 min readRead more
Stories in this topic are being prepared.
© Before the Conclusion · Original editorial work, AI-assisted imagery. Please request permission before reuse.